CONTENTS

Preface. By VASSIL ST. GEORGIEV and HIDEYO YAMAGUCHI ............ xv

Immunomodulating Drugs: Major Advances in Research and Development. By VASSIL ST. GEORGIEV ......................... 1

Part I. FK-506: Chemistry and Biological Evaluation
FK-506: Its Role in Immunosuppression. By B. G. CHRISTENSEN ... 11

Discovery of FK-506 and Update. By TORU KINO and TOSHIO GOTO .................................................. 13


Structural Studies of Complexed FK-506 Binding Protein. By Jon CLARDY ...................................................... 37

Allograft and Xenograft Acceptance under FK-506 and Other Immunosuppressant Treatment. By THOMAS E. STARZL, NORIKO MURASE, ANTHONY J. DEMETRIS, SUZANNE ILSTAD, CAMILLO RICORDI, and MASSIMO TRUCCO .............. 46

FK-506 Inhibits the IL-2-Independent Induction of the Activation Antigen CD 69. By GABRIELLE H. REEM, YONG SHI, and SOUMAYA EL ROUBY .................................................. 52

*This volume is the result of a conference entitled Third International Conference on Drug Research in Immunologic and Infectious Diseases: Immunomodulating Drugs—Synthesis, Preclinical and Clinical Evaluation held by the New York Academy of Sciences on June 27-July 1, 1992 in Washington, D.C.

Part II. Immunosuppressive Properties of Rapamycin

Rapamycin: *In Vitro* Profile of a New Immunosuppressive Macrolide. By S. N. SEHGAL and C. C. BANSBACH .......................... 58

Prevention and Treatment of Allograft Rejection *in Vivo* by Rapamycin: Molecular and Cellular Mechanisms of Action. By RANDALL ELLIS MORRIS .......................... 68


Effects of Orally Administered Rapamycin in Animal Models of Arthritis and Other Autoimmune Diseases. By RICHARD P. CARLSON, WILLIAM L. BAEDER, ROBERT G. CACCESE, LINDA M. WARNER, and SUREN N. SEHGAL .......................... 86

Rapamycin’s Inhibition of Thymocyte Proliferation, Unlike That of Cyclosporin A or Prednisolone, Is Not Associated with Cytotoxicity. By CATHERINE C. BANSBACH, DAVID WANCIO, ROBERT G. CACCESE, C. FRANK SHEN, and SUREN N. SEHGAL .......................... 114

Rapamycin Inhibits Lymphocyte Proliferation in a Popliteal Lymph Node Model via an IL-2-Independent Mechanism. By L. M. WARNER, G. M. LEWIS, B. M. WEICHMAN, and S. N. SEHGAL .......................... 117


Part III. 15-Deoxyspergualin: Chemistry and Immunosuppressive Action

Synthesis and Background Chemistry of 15-Deoxyspergualin. By KENJI MAEDA, YOSHIHISA UMEDA, and TETSUSHI SAINO .......................... 123

15-Deoxyspergualin, a Novel Immunosuppressive Drug: Studies of the Mechanism of Action. By MARK A. TEPPER, STEVEN NADLER, CHARLES MAZZUCCO, CHERRY SINGH, and SUSAN L. KELLEY .......................... 136
Successful Treatment with a Novel Immunosuppressive Agent, Deoxyspergualin, in Type II Collagen-Induced Arthritis in Mice. By KYUICHI NEMOTO, TAKAKO MAE, FUMINORI ABE, and TOMIO TAKEUCHI ........................................... 148

Preclinical Studies with 15-Deoxyspergualin in Various Animal Models for Autoimmune Diseases. By HANS-ULRICH SCHORLEMMER and GERHARD DICKNEITE ........................................... 155

15-Deoxyspergualin: A Novel Immunosuppressive Drug with Clinical Potential. By FRANCIS T. THOMAS, MARK A. TEPPER, JUDITH M. THOMAS, and CARL E. HAISCH ........................................... 175

Deoxyspergualin in Allogeneic Kidney and Xenogeneic Islet Transplantation: Early Clinical Trials. By CARL G. GROTH ........................................... 193

Deoxyspergualin: Clinical Trials in Renal Graft Rejection. By HIROSHI AMEMIYA FOR THE JAPAN COLLABORATIVE TRANSPLANT STUDY OF DEOXYSPERGUALIN ........................................... 196

A Member of the Hsp70 Family of Heat-Shock Proteins Is a Putative Target for the Immunosuppressant 15-Deoxyspergualin. By CHARLES E. MAZZUCCO and STEVEN G. NADLER ........................................... 202

Effects of 15-Deoxyspergualin on the Expression of Surface Immunoglobulin in 70Z/3.12 Murine Pre-B Cell Line. By KRISTINE G. STERBENZ and MARK A. TEPPER ........................................... 205

Part IV. Guanine Arabinoside and Purine Nucleoside Phosphorylase Inhibitors

Enzymes of the Purine Metabolism: Inhibition and Therapeutic Potential. By VASSIL ST. GEORGIEV ........................................... 207

IMP Dehydrogenase Inhibitors as Immunomodulators. By BEVERLY S. MITCHELL, JENNIFER S. DAYTON, LAURENCE A. TURKA, and CRAIG B. THOMPSON ........................................... 217

Guanine Arabinoside as a Bone Marrow-Purging Agent. By JOANNE KURTZBERG ........................................... 225


Part V. Immunomodulating Activity of Experimental Therapeutics


Experimental Modulation of IL-1 Production and Cell Surface Molecule Expression by Levamisole. By Edward S. Kimball ........................................................................................................ 259

Recent Clinical Trials with Levamisole. By Michael R. Kurman ... 269

Sex Hormones as Immunomodulators of Disease. By Robert G. Lahita ................................................................................................................................. 278

Corticosteroids as Immunomodulators. By Henry N. Claman ... 288

Androstenediol Regulates Systemic Resistance against Lethal Infections in Mice. By Roger M. Loria and David A. Padgett .......................................................... 293

Overview on the Chemistry and Immunomodulating Properties of Novel Pyrimidinones. By Wendell Wierenga ......................................................... 296

Bropirimine in Bladder Cancer: Clinical Studies. By Michael F. Sarosdy ............................................................................................................................. 301

Immunosuppressive Activity of Mycophenolate Mofetil. By Elsie M. Eugui and Anthony C. Allison .............................................................. 309

Molecular Mechanisms of Immunosuppression by Cyclosporins. By Gerhard Zenke, Götz Baumann, Roland Wenger, Peter Hiestand, Valerie Quesniaux, Elsebeth Andersen, and Max H. Schreier ................................................................. 330


Suppression of Alloantigen Presentation by Prodigiosin, a T Cell-Specific Immunosuppressant. By Junji Magae, Masahiro Yamashita, and Kazuo Nagai ......................................................... 339

In Vivo and in Vitro Efficacy of Fusidic Acid in HIV Infection. By Giuseppe Famularo, Claudio De Simone, Sonia Tzantzoglou, Vito Trinchieri, Sonia Moretti, and Giorgio Tonietti .......................................................... 341

In Vivo Antitumor Activity of the Hypoxanthine Derivatives ST 789 and ST 689. By Claudio De Simone, Giuseppe Famularo, Pietro Foresta, Claudio Albertoni, and Edoardo Arrigoni Martelli ......................................................... 344

Syntheses of Macromolecular Immunomodulators and Conjugates Employing Haloacetyl Reagents. By John K. Inman ....................... 347

Immunomodulating Activity of Myelopeptides: Clinical Trials. By Rem V. Petrov .......................................................... 351
Structural Nature and Functions of Transfer Factors. By Charles H. Kirkpatrick .......................................................... 362


Antitumor and Antimicrobial Activities of Enterococcal Preparation Orally Administered to Mice. By Shigeru Abe, Kazutomo Ohashi, Kastuhisa Uchida, Tatsuji Ikeda, Sadao Kimura, and Hideyo Yamaguchi .......................................................... 372

Immunostimulating Peptide Derived from Soybean Protein. By Masaaki Yoshikawa, Katsuki Kishi, Masakazu Takahashi, Akihiro Watanabe, Tsuyoshi Miyamura, Masatoshi Yamazaki, and Hideo Chiba ................................................. 375

Two Simple Glucose Derivatives with Opposite Immunoactivities. By Mei-Ling Shen, Shi-Kang Zhai, Zhen-Wei Lu, and David W. Ou .......................................................... 377


CONFERENCE LECTURESHIPS

The Edward Jenner Lecture
Biological Spinoffs of Organ Transplantation. By Joseph E. Murray .......................................................... 389

The George Hitchings and Gertrude Elion Lecture
The Pharmacology of Azathioprine. By Gertrude B. Elion .......................................................... 401

The Jules Bordet Lecture
Immunopathogenesis of HIV Infection. By Anthony S. Fauci .......................................................... 409

The Gerhard Domagk Lecture
Transcription Factors in Lymphoid Development. By David Baltimore .......................................................... 421

The Emil von Behring Lecture*
Development and Functions of Gamma Delta T Cells. By Susumu Tonegawa .......................................................... 429

*Not submitted.
Part VI. Immunomodulating Activities of Anti-Infectious Drugs

Immunomodulating Drugs: Whence and Whither. By GEORGE DE STEVENS .......................................................... 430


Immunomodulating Activity of Antifungal Drugs. By HIDEYO YAMAGUCHI, SHIGERU ABE, and YOSHIKO TOKUDA ............. 447

Immunopharmacologic Properties of Inosine 5'-Methyl Monophosphate (MIMP). By M. SOSA, A. SAHA, A. GINER-SOROLLA, E. HADDEN, and J. W. HADDEN ....................... 458

Immunomodulatory Properties of AZT. By ROBERT J. MCKALLIP, MITZI NAGARKATTI, and PRAKASH NAGARKATTI ..................... 464

Antiviral Activity of a Synthetic Double-Stranded Polyribonucleotide Interferon Inducer in a Murine AIDS Retrovirus Model. By PAUL L. BLACK, KATHERINE M. MCKINNON, SHARON L. WOODEN, and MICHAEL A. USSERY ...................... 467

Part VII. Treatment of Infectious Diseases and Sepsis: Intervention by Immune Regulation

Modulation of Cytokine Responses in Sepsis. By STEPHEN F. LOWRY and LYLE L. MOLDAWER ........................................ 471

Interventions for the Treatment of Septic Shock. By IRENE S. FIGARI and MICHAEL A. PALLADINO ........................................ 483

Pleiotropic Effects of Transforming Growth Factor-β on Cells of the Immune System. By FRANCIS RUSCETTI, LUIGI VARESIO, AUGUSTO OCHOA, and JOHN ORTALDO ....................... 488

TGFβ and HIV Infection. By MARTIN LOTZ and PRADEEP SETH ... 501

Part VIII. Immunomodulating Properties of Peptides in Allergic and Autoimmune Diseases

Cytokines and Modulation of Diseases of Immediate Hypersensitivity. By MARSHALL PLAUT ........................................ 512

Therapeutic Peptides That Block Interaction of T Cells with MHC in Experimental Allergic Encephalomyelitis. By LAWRENCE STEINMAN ......................................................... 521

Antigen Presentation by the Murine Renal Proximal Tubule: A Mechanism of Self Tolerance? By DAVID T. HAGERTY and PAUL M. ALLEN ................................................ 525
Part IX. Kampo Medicine (Japanese Herbal Medicine) and Its Immunomodulating Effects with Special Reference to Intractable Asthma

Immunologic Aspects of Kampo Medicine. By IKURO KIMURA

Inhibition of Hypersensitivity Reactions by Saiboku-to (TJ-96), Particularly on Type IV Reaction. By AKIHIDE KODA

Effect of Saiboku-to (TJ-96) on Bronchial Asthma: Induction of Glucocorticoid Receptor, β-Adrenaline Receptor, IgE-Fcε Receptor Expression and Its Effect on Experimental Immediate and Late Asthmatic Reaction. By SHIGENORI NAKAJIMA, YUJI TOHDA, KENTARO OHKAWA, JUNICHI CHIHARA, and YUKIO NAGASAKA

Effect of an Herbal Preparation, Saiboku-to (TJ-96), on Antigen-Induced Airway Hyperresponsiveness and Eosinophil Infiltration in Actively Sensitized Guinea Pigs. By M. TODA, S. MOTOJIMA, T. FUKUDA, and S. MAKINO

Effects of Saiboku-to (TJ-96) on the Production of Platelet-Activating Factor in Human Neutrophils. By TSUNEYOSHI NAKAMURA, Motoaki KURIYAMA, ERI KOSUGE, Keiko ISHIHARA, and KOJI ITO

A Multicenter Clinical Trial of TJ-96 in Patients with Steroid-Dependent Bronchial Asthma: A Comparison of Groups Allocated by the Envelope Method. By YOSUKE EGASHIRA and HITOSHI NAGANO

Part X. Cytokines and Regulation of the Immune Response

Cytokines and Their Role as Growth Factors and in Regulation of Immune Responses. By VASSIL ST. GEORGIEV and JOSEPH F. ALBRIGHT

The Interleukin-2 Receptor: A Target for Immunotherapy. By THOMAS A. WALDMANN, CAROLYN GOLDMAN, LOIS TOP, ANGUS GRANT, JACK BURTON, RICHARD BAMFORD, ERICH ROESSLER, IVAN HORAK, SARA ZAKNOEN, CLAUDE KASTENSPORTES, JEFFREY WHITE, RICHARD ENGLAND, EVA HORAK, JEAN MARTINUCCI, Sikiru A. Tinubu, BIBHUTI MISHRA, RICHARD JUNGHANS, MICHAEL DIPRE, JORGE CARRASQUILLO, JAMES REYNOLDS, OTTO GANSOW, and DAVID NELSON

The Role of the T Cell Receptor α Chain in Antigen-Specific Immune Suppression. By MICHAEL C. BYRNE, RICHARD M. O'HARA, Jr., VIJAY K. KUCHROO, SUNDARARAJAN JAYARAMAN, ANJANA RAO, MARTIN E. DORF, and MARY COLLINS
Increased Levels of Leukotriene B_4 and Interleukin-8 in Psoriatic Skin. By Renza Degiulio, Caterina Montemartini, Antonino Mazzone, Davide Pasotti, Antonio Donadini, and Giovanni Ricevuti

NK Cells and Interferon as Mediators of Biological Response Modifier-Mediated Protection against MCMV and HSV-2 Infection in Normal and Immunocompromised Mice. By S. C. Kunder and P. S. Morahan

Part XI. Drug Metabolizing Enzymes and the Immune System

Immune Dysfunction Related to Drug-Metabolizing Enzymes. By Joseph F. Albright

Role of the Ah Receptor and the Dioxin-Inducible (Ah) Gene Battery in Toxicity, Cancer, and Signal Transduction. By Daniel W. Nebert, Alvaro Puga, and Vasilis Vasiliou

Autoantibodies against Cytochromes P-450 in Drug-Induced Autoimmune Hepatitis. By P. H. Beaune and M. Bourdi

Immunity to Halothane Metabolite-Modified Proteins in Halothane Hepatitis. By J. Gerald Kenna, Trudy L. Knight, and Frank N. A. M. van Pelt


Part XII. Novel Strategies for Immunotherapy

Immunologic Approaches to the Therapy of HIV-1 Infection. By Michael C. Sneller and H. Clifford Lane

Gene Transfer for Therapy and Prophylaxis of HIV-1 Infection. By Mark L. Rohrbaugh and John J. McGowan

Modulation of Macrophage Function by Transforming Growth Factor β, Interleukin 4, and Interleukin 10. By Christian Bogdan and Carl Nathan

Pseudomonas Exotoxin and Recombinant Immunotoxins Derived from It. By David Fitzgerald and Ira Pastan

Superantigens in Infectious Diseases, Including AIDS. By Jeffrey Laurence, Andrew S. Hodes, and David N. Posnett

Specific RNA Drug Therapy of Hepatitis Viruses. By WILLIAM A. CARTER, ROBERT J. SUHADOLNIK, WERNER E. G. MÜLLER, BRENT E. KORBA, HOWARD R. HUBBELL, GABRIEL GARCIA, and DAVID R. STRAYER .................................................. 758

Immunorehabilitation in Patients with Herpes Simplex. By TENGIZ TSERTSVADZE, NIKOLAI SHAVDIA, IRAKLI MEBONIA, TSISANA SHARTAVA, MANANA GVABERIDZE, and MALVINA ALADASHVILI .................................................. 762

Quantitative Determination of HLA-DR Antigen Expression on Cell Surfaces with Monoclonal Antibody by Dot-ELISA. By ZHAO XIAOJUAN and ZHANG JIYING .................................................. 765

Role of Increase of Opioid Receptors in Granulocyte CD11b/CD18 Dysfunction. By ANTONINO MAZZONE, GIOVANNI RICEVUTI, DAVIDE PASOTTI, GIANLUCA FOSSATI, IOLANDA MAZZUCHELLI, PAOLA CAVIGLIANO, SERGIO LECCHINI, GIANMARIO FRIGO, and ANTONIA NOTARIO .................................................. 770

Immunosuppressive Effects of Lymphocyte-Specific Histamine Congener Treatment of an Adoptive Transfer Model. By NINA K. GARLIE, PARISA KHOSROPOUR, and KENNETH L. MELMON .................................................. 774

Part XIII. Vaccines: Recent Progress in Development

Issues in the Development of a Prophylactic HIV Vaccine. By DANIEL HOTH .................................................. 777

T Cell Vaccines for Autoimmune Diseases. By FELIX MOR and IRUN R. COHEN .................................................. 784

Vaccines Based on Synthetic Polyions and Peptides. By RAKHIM M. KHAITOV .................................................. 788

Advances in Influenza Virus Vaccine Research. By ROBERT B. COUCH .................................................. 803

Index of Contributors .................................................. 813